PPD, Inc. has opened offices in Sydney, Australia; Copenhagen, Denmark; Lisbon, Portugal; and Lima, Peru. The company says the moves reflect “continued expansion of its Phase II-IV services in key therapeutic areas.”

The four new offices broaden the company’s global footprint for delivering clinical services in response to increasing client demand. Sydney marks  PPD’s second location in Australia, while the locations in Copenhagen, Lisbon and Lima establish PPD’s first offices in those countries.

“With the biopharmaceutical industry increasingly relying on outsourcing, these new offices are important to our strategic growth in areas where there is high demand for our global experience and therapeutic expertise,” said Fred Eshelman, chief executive officer of PPD. “We will continue to execute our globalization strategy by positioning our people, systems and infrastructure in locations that meet the needs of our clients.”